Semin intervent Radiol 2014; 31(01): 027-032
DOI: 10.1055/s-0033-1363840
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Surgical Management of Renal Cell Carcinoma

Laura-Maria Krabbe
1   Department of Urology, the University of Muenster Medical Center, Muenster, Germany
2   Department of Urology, UT Southwestern Medical Center, Dallas, Texas
,
Aditya Bagrodia
2   Department of Urology, UT Southwestern Medical Center, Dallas, Texas
,
Vitaly Margulis
2   Department of Urology, UT Southwestern Medical Center, Dallas, Texas
,
Christopher G. Wood
3   Department of Urology, MD Anderson Cancer Center, Houston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
20 February 2014 (online)

Abstract

Surgical resection of renal cell carcinoma (RCC) is the benchmark for long-term cure of the disease. Although open or laparoscopic radical nephrectomy is considered the gold standard for stage T1b-T4 tumors, nephron-sparing surgery is the preferred operative modality for small renal masses demonstrating equivalent oncologic efficacy and improved renal function outcomes compared with complete nephrectomy. With the advance of minimally invasive surgery, nephron-sparing procedures can safely be conducted laparoscopically with or without robotic assistance. RCC with intravenous tumor thrombus presents a surgical challenge, but multidisciplinary surgical approaches can provide long-term benefit in these patients. The role of cytoreductive nephrectomy and metastasectomy in patients with metastatic RCC (mRCC) is controversial, but seems to be beneficial for patients in the era of targeted therapy.

 
  • References

  • 1 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 (1) 11-30
  • 2 Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. N Engl J Med 2010; 362 (7) 624-634
  • 3 Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353 (23) 2477-2490
  • 4 Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer 2004; 100 (4) 738-745
  • 5 Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008; 34 (3) 193-205
  • 6 Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005; 173 (6) 1853-1862
  • 7 Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012; 23 (Suppl. 08) viii35-40
  • 8 Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101 (3) 297-301
  • 9 Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281 (17) 1628-1631
  • 10 Kerbl K, Clayman RV, Mc Dougall E, Kavoussi LR. Laparoscopic nephrectomy: current status. Arch Esp Urol 1993; 46 (7) 581-584
  • 11 Becker F, Siemer S, Humke U, Hack M, Ziegler M, Stöckle M. Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: long-term survival data of 216 patients. Eur Urol 2006; 49 (2) 308-313
  • 12 Sagalowsky AI, Kadesky KT, Ewalt DM, Kennedy TJ. Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 1994; 151 (5) 1181-1184
  • 13 Sandock DS, Seftel AD, Resnick MI. Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Urology 1997; 49 (1) 28-31
  • 14 Tsui KH, Shvarts O, Barbaric Z, Figlin R, de Kernion JB, Belldegrun A. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J Urol 2000; 163 (2) 437-441
  • 15 Blom JH, van Poppel H, Maréchal JM , et al; EORTC Genitourinary Tract Cancer Group. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009; 55 (1) 28-34
  • 16 Schafhauser W, Ebert A, Brod J, Petsch S, Schrott KM. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticancer Res 1999; 19 (2C): 1573-1578
  • 17 Capitanio U, Jeldres C, Patard JJ , et al. Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma. BJU Int 2009; 103 (1) 33-37
  • 18 Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990; 143 (3) 468-473 , discussion 473–474
  • 19 Saitoh H, Nakayama M, Nakamura K, Satoh T. Distant metastasis of renal adenocarcinoma in nephrectomized cases. J Urol 1982; 127 (6) 1092-1095
  • 20 Kerbl K, Clayman RV, McDougall EM, Kavoussi LR. Laparoscopic nephrectomy. BMJ 1993; 307 (6917) 1488-1489
  • 21 Gill IS, Meraney AM, Schweizer DK , et al. Laparoscopic radical nephrectomy in 100 patients: a single center experience from the United States. Cancer 2001; 92 (7) 1843-1855
  • 22 Chan DY, Cadeddu JA, Jarrett TW, Marshall FF, Kavoussi LR. Laparoscopic radical nephrectomy: cancer control for renal cell carcinoma. J Urol 2001; 166 (6) 2095-2099 , discussion 2099–2100
  • 23 Wille AH, Roigas J, Deger S, Tüllmann M, Türk I, Loening SA. Laparoscopic radical nephrectomy: techniques, results and oncological outcome in 125 consecutive cases. Eur Urol 2004; 45 (4) 483-488 , discussion 488–489
  • 24 Hemal AK, Kumar A, Gupta NP, Kumar R. Oncologic outcome of 132 cases of laparoscopic radical nephrectomy with intact specimen removal for T1-2N0M0 renal cell carcinoma. World J Urol 2007; 25 (6) 619-626
  • 25 Dunn MD, Portis AJ, Shalhav AL , et al. Laparoscopic versus open radical nephrectomy: a 9-year experience. J Urol 2000; 164 (4) 1153-1159
  • 26 McDougall E, Clayman RV, Elashry OM. Laparoscopic radical nephrectomy for renal tumor: the Washington University experience. J Urol 1996; 155 (4) 1180-1185
  • 27 Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes?. J Urol 2009; 181 (1) 55-61 , discussion 61–62
  • 28 Huang WC, Levey AS, Serio AM , et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7 (9) 735-740
  • 29 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351 (13) 1296-1305
  • 30 Campbell SC, Novick AC, Belldegrun A , et al; Practice Guidelines Committee of the American Urological Association. Guideline for management of the clinical T1 renal mass. J Urol 2009; 182 (4) 1271-1279
  • 31 Van Poppel H, Da Pozzo L, Albrecht W , et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011; 59 (4) 543-552
  • 32 Novick AC. Renal-sparing surgery for renal cell carcinoma. Urol Clin North Am 1993; 20 (2) 277-282
  • 33 Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999; 162 (6) 1930-1933
  • 34 Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol 2000; 163 (3) 730-736
  • 35 Crépel M, Jeldres C, Sun M , et al. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma. Urology 2010; 76 (4) 883-888
  • 36 Leibovich BC, Blute M, Cheville JC, Lohse CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004; 171 (3) 1066-1070
  • 37 Patard JJ, Shvarts O, Lam JS , et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004; 171 (6 Pt 1) 2181-2185 , quiz 2435
  • 38 Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG. Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int 2007; 100 (6) 1235-1239
  • 39 Castilla EA, Liou LS, Abrahams NA , et al. Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology 2002; 60 (6) 993-997
  • 40 Sutherland SE, Resnick MI, Maclennan GT, Goldman HB. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter?. J Urol 2002; 167 (1) 61-64
  • 41 Marszalek M, Carini M, Chlosta P , et al. Positive surgical margins after nephron-sparing surgery. Eur Urol 2012; 61 (4) 757-763
  • 42 Lesage K, Joniau S, Fransis K, Van Poppel H. Comparison between open partial and radical nephrectomy for renal tumours: perioperative outcome and health-related quality of life. Eur Urol 2007; 51 (3) 614-620
  • 43 Thompson RH, Lane BR, Lohse CM , et al. Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney. Urology 2012; 79 (2) 356-360
  • 44 Becker F, Van Poppel H, Hakenberg OW , et al. Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol 2009; 56 (4) 625-634
  • 45 Nguyen MM, Gill IS. Halving ischemia time during laparoscopic partial nephrectomy. J Urol 2008; 179 (2) 627-632 , discussion 632
  • 46 Thompson RH, Lane BR, Lohse CM , et al. Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol 2010; 58 (3) 331-336
  • 47 Permpongkosol S, Bagga HS, Romero FR, Sroka M, Jarrett TW, Kavoussi LR. Laparoscopic versus open partial nephrectomy for the treatment of pathological T1N0M0 renal cell carcinoma: a 5-year survival rate. J Urol 2006; 176 (5) 1984-1988 , discussion 1988–1989
  • 48 Kyllo RL, Tanagho YS, Kaouk JH , et al. Prospective multi-center study of oncologic outcomes of robot-assisted partial nephrectomy for pT1 renal cell carcinoma. BMC Urol 2012; 12: 11
  • 49 Lucas SM, Mellon MJ, Erntsberger L, Sundaram CP. A comparison of robotic, laparoscopic and open partial nephrectomy. JSLS 2012; 16 (4) 581-587
  • 50 Froghi S, Ahmed K, Khan MS, Dasgupta P, Challacombe B. Evaluation of robotic and laparoscopic partial nephrectomy for small renal tumours (T1a). BJU Int 2013; 112 (4) E322-E333
  • 51 Aboumarzouk OM, Stein RJ, Eyraud R , et al. Robotic versus laparoscopic partial nephrectomy: a systematic review and meta-analysis. Eur Urol 2012; 62 (6) 1023-1033
  • 52 Miller DC, Daignault S, Wolf Jr JS , et al. Hospital characteristics and use of innovative surgical therapies among patients with kidney cancer. Med Care 2008; 46 (4) 372-379
  • 53 Lawindy SM, Kurian T, Kim T , et al. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. BJU Int 2012; 110 (7) 926-939
  • 54 Capitanio U, Shariat SF, Isbarn H , et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 2009; 56 (1) 1-9
  • 55 Kwon TW, Kim H, Moon KM , et al. Surgical treatment of inferior vena cava tumor thrombus in patients with renal cell carcinoma. J Korean Med Sci 2010; 25 (1) 104-109
  • 56 Gettman MT, Boelter CW, Cheville JC, Zincke H, Bryant SC, Blute ML. Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol 2003; 169 (4) 1282-1286
  • 57 Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 2004; 94 (1) 33-41
  • 58 Haferkamp A, Bastian PJ, Jakobi H , et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol 2007; 177 (5) 1703-1708
  • 59 Klatte T, Pantuck AJ, Riggs SB , et al. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol 2007; 178 (4 Pt 1) 1189-1195 , discussion 1195
  • 60 Sweeney P, Wood CG, Pisters LL , et al. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol 2003; 21 (5) 327-333
  • 61 Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R ; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358 (9286) 966-970
  • 62 Flanigan RC, Salmon SE, Blumenstein BA , et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345 (23) 1655-1659
  • 63 Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171 (3) 1071-1076
  • 64 Trinh QD, Bianchi M, Hansen J , et al. In-hospital mortality and failure to rescue after cytoreductive nephrectomy. Eur Urol 2012; (Sep): 7
  • 65 Bigot P, Lebdai S, Ravaud A , et al. The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies. World J Urol 2013; (Mar): 30
  • 66 Choueiri TK, Xie W, Kollmannsberger C , et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011; 185 (1) 60-66
  • 67 Kierney PC, van Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol 1994; 1 (4) 345-352
  • 68 Siemer S, Lehmann J, Kamradt J , et al. Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. J Urol 2004; 171 (6 Pt 1) 2155-2159 , discussion 2159
  • 69 Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011; 117 (13) 2873-2882
  • 70 Tosco L, Van Poppel H, Frea B, Gregoraci G, Joniau S. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol 2013; 63 (4) 646-652
  • 71 Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 2009; 181 (5) 2044-2051